Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
作者信息
Heysell Scott K, Ahmed Shahriar, Rahman Md Toufiq, Akhanda Md Wahiduzzaman, Gleason A Tucker, Ebers Andrew, Houpt Eric R, Banu Sayera
机构信息
Division of Infectious Diseases and International Health, University of Virginia, Charlottesvile, VA, USA.
These authors contributed equally.
出版信息
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.01778-2017. Print 2018 Mar.
Abstract
摘要
相似文献
1
Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.孟加拉国使用卡那霉素治疗耐多药结核病时出现的听力损失。
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.01778-2017. Print 2018 Mar.
2
Adverse effects of aminoglycosides in children with drug resistant tuberculosis.氨基糖苷类药物在耐药性肺结核儿童中的不良反应。
Infect Dis (Lond). 2019 Mar;51(3):230-233. doi: 10.1080/23744235.2018.1540884. Epub 2018 Nov 30.
3
[Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].[耐多药结核病治疗期间卡那霉素引起的耳毒性]
Rev Mal Respir. 2020 May;37(5):369-375. doi: 10.1016/j.rmr.2019.12.005. Epub 2020 Apr 8.
4
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.强化治疗的耐药结核病患者中氨基糖苷类药物所致耳毒性的临床预测因素
Auris Nasus Larynx. 2017 Aug;44(4):404-410. doi: 10.1016/j.anl.2016.10.005. Epub 2016 Nov 8.
5
Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.在纳米比亚一项回顾性队列研究中，比较在项目实施条件下多药耐药结核病治疗中阿米卡星和卡那霉素引起的听力损失情况。
BMC Pharmacol Toxicol. 2015 Dec 10;16:36. doi: 10.1186/s40360-015-0036-7.
6
Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.在耐多药结核病治疗中，氨基糖苷类药物治疗药物监测与听力损失几率降低相关。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01400-16. Print 2017 Mar.
7
Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.抗多药肺结核患者卡那霉素致聋的药代动力学及其他危险因素。
Int J Audiol. 2020 Mar;59(3):219-223. doi: 10.1080/14992027.2019.1690170. Epub 2019 Nov 18.
8
Hearing loss in children treated for multidrug-resistant tuberculosis.儿童耐多药结核病治疗后的听力损失。
J Infect. 2013 Apr;66(4):320-9. doi: 10.1016/j.jinf.2012.09.002. Epub 2012 Sep 6.
9
Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.南非耐多药结核病患者中先前存在听力损失的患病率。
Am J Audiol. 2020 Jun 8;29(2):199-205. doi: 10.1044/2020_AJA-19-00103. Epub 2020 Apr 22.
10
Hear this! Audiometry testing saves the hearing of a patient with drug-resistant tuberculosis.听着！听力测试挽救了一名耐多药结核病患者的听力。
Int J Tuberc Lung Dis. 2019 Mar 1;23(3):378-379. doi: 10.5588/ijtld.18.0558.
引用本文的文献
1
A Dual-Signal Electrochemiluminescence Sensor for Kanamycin Detection Based on a Self-Enhanced Zr MOF and Single Co-Reactant Competition Mechanism.基于自增强锆基金属有机框架和单共反应剂竞争机制的用于卡那霉素检测的双信号电化学发光传感器。
Biosensors (Basel). 2025 May 5;15(5):291. doi: 10.3390/bios15050291.
2
Multiple mechanisms of aminoglycoside ototoxicity are distinguished by subcellular localization of action.氨基糖苷类耳毒性的多种机制可通过作用的亚细胞定位来区分。
Front Neurol. 2024 Nov 14;15:1480435. doi: 10.3389/fneur.2024.1480435. eCollection 2024.
3
Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with Multi-Drug Resistance.印度多药耐药儿童二线抗结核药物的药代动力学-药效学（PK-PD）分析
Indian J Pediatr. 2024 May 28. doi: 10.1007/s12098-024-05135-9.
4
MultiGML: Multimodal graph machine learning for prediction of adverse drug events.MultiGML：用于预测药物不良事件的多模态图机器学习
Heliyon. 2023 Aug 27;9(9):e19441. doi: 10.1016/j.heliyon.2023.e19441. eCollection 2023 Sep.
5
A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.一个关联了 12289 株结核分枝杆菌分离株基因组与 13 种抗生素定量耐药表型的数据集。
PLoS Biol. 2022 Aug 9;20(8):e3001721. doi: 10.1371/journal.pbio.3001721. eCollection 2022 Aug.
6
Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen.病例报告：卡那霉素耳毒性与耐多药结核病治疗方案
Int Med Case Rep J. 2021 Nov 26;14:815-817. doi: 10.2147/IMCRJ.S336259. eCollection 2021.
7
Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.抗多药肺结核患者卡那霉素致聋的药代动力学及其他危险因素。
Int J Audiol. 2020 Mar;59(3):219-223. doi: 10.1080/14992027.2019.1690170. Epub 2019 Nov 18.
8
Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis.多药耐药结核病不良结局预测模型。
Rev Saude Publica. 2019 Sep 23;53:77. doi: 10.11606/s1518-8787.2019053001151. eCollection 2019.
本文引用的文献
1
Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.糖尿病与耐多药结核病的严重不良事件相关。
Arch Bronconeumol. 2017 May;53(5):245-250. doi: 10.1016/j.arbres.2016.10.021. Epub 2017 Jan 11.
2
Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.在耐多药结核病治疗中，氨基糖苷类药物治疗药物监测与听力损失几率降低相关。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01400-16. Print 2017 Mar.
3
Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.人工智能与阿米卡星暴露对耐多药结核病患者预后的预测
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5928-32. doi: 10.1128/AAC.00962-16. Print 2016 Oct.
4
Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis.对接受卡那霉素治疗耐多药结核病患者的听力学评估
Iran J Otorhinolaryngol. 2016 May;28(86):203-8.
5
Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials.耐多药结核病的短程治疗：STREAM试验
Eur Respir Rev. 2016 Mar;25(139):29-35. doi: 10.1183/16000617.0080-2015.
6
A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB.系统评价和荟萃分析 N-乙酰半胱氨酸预防氨基糖苷类药物致聋的疗效和安全性：对耐多药结核病治疗的影响。
Thorax. 2015 Nov;70(11):1070-7. doi: 10.1136/thoraxjnl-2015-207245. Epub 2015 Sep 7.
7
Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.孟加拉国耐多药结核病患者的定量药物敏感性：对治疗方案选择的影响
PLoS One. 2015 Feb 24;10(2):e0116795. doi: 10.1371/journal.pone.0116795. eCollection 2015.
8
Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.包括阿米卡星在内的成功耐多药结核病治疗方案与高听力损失率相关。
BMC Infect Dis. 2014 Oct 9;14:542. doi: 10.1186/1471-2334-14-542.
9
Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients.HIV 阳性和 HIV 阴性耐多药结核病患者的氨基糖苷类药物诱导性听力损失。
S Afr Med J. 2012 May 8;102(6 Pt 2):363-6. doi: 10.7196/samj.4964.
10
Household costs of illness during different phases of tuberculosis treatment in Central Asia: a patient survey in Tajikistan.塔吉克斯坦的一项患者调查：不同结核病治疗阶段的疾病家庭负担。
BMC Public Health. 2010 Jan 18;10:18. doi: 10.1186/1471-2458-10-18.
Zotero 插件